KalVista Pharmaceuticals (KALV) Return on Capital Employed (2015 - 2025)
KalVista Pharmaceuticals recorded quarterly Return on Capital Employed of 104.78% in Q3 2025, down 23.25% quarter-over-quarter from 85.01% in Q2 2025, and down 2516.0% year-over-year from 4.34% in Q3 2024.
KalVista Pharmaceuticals' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 104.78% for Q3 2025.
- In Q3 2025, Return on Capital Employed fell 2516.0% year-over-year to 104.78%; the TTM figure through Jul 2025 stood at 104.78% (down 2516.0% YoY), while the FY2025 annual figure was 94.99%, down 1968.0% from the prior year.
- Return on Capital Employed came in at 104.78% for Q3 2025 at KalVista Pharmaceuticals, down from 85.01% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 24.48% in Q3 2021 to a low of 115.38% in Q1 2024.
- A 5-year average of 69.27% and a median of 68.82% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 3914 bps in 2021 and tumbled 5361 bps in 2024, its largest moves.
- KalVista Pharmaceuticals' Return on Capital Employed stood at 30.58% in 2021, then slumped by 114 bps to 65.54% in 2022, then plunged by 36 bps to 89.17% in 2023, then decreased by 22 bps to 108.39% in 2024, then gained by 3 bps to 104.78% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 104.78%, 85.01%, and 108.39% for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -104.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -104.78% |
| Apr 30, 2025 | -85.01% |
| Oct 31, 2024 | -108.39% |
| Jul 31, 2024 | -79.62% |
| Apr 30, 2024 | -92.47% |
| Jan 31, 2024 | -115.38% |
| Oct 31, 2023 | -89.17% |
| Jul 31, 2023 | -72.10% |
| Apr 30, 2023 | -62.18% |
| Jan 31, 2023 | -61.76% |
| Oct 31, 2022 | -65.54% |
| Jul 31, 2022 | -56.40% |
| Apr 30, 2022 | -47.62% |
| Jan 31, 2022 | -39.08% |
| Oct 31, 2021 | -30.58% |
| Jul 31, 2021 | -24.48% |
| Apr 30, 2021 | -36.35% |
| Jan 31, 2021 | -75.94% |
| Oct 31, 2020 | -69.73% |
| Jul 31, 2020 | -56.94% |
| Apr 30, 2020 | -45.03% |
| Jan 31, 2020 | -43.83% |
| Oct 31, 2019 | -34.85% |
| Jul 31, 2019 | -30.82% |
| Apr 30, 2019 | -28.60% |
| Jan 31, 2019 | -19.45% |
| Oct 31, 2018 | -25.92% |
| Jul 31, 2018 | -55.36% |
| Apr 30, 2018 | -45.84% |
| Jan 31, 2018 | -78.23% |
| Oct 31, 2017 | -84.08% |
| Jul 31, 2017 | -78.95% |
| Apr 30, 2017 | -67.35% |
| Mar 31, 2016 | -45.90% |
| Dec 31, 2015 | -38.13% |
| Sep 30, 2015 | -31.18% |
| Jun 30, 2015 | -49.49% |
| Mar 31, 2015 | 333.45% |